TY - JOUR
T1 - A novel interaction between soluble epoxide hydrolase and the AT1 receptor in retinal microvascular damage
AU - Wang, Mong Heng
AU - Ibrahim, Ahmed S.
AU - Hsiao, George
AU - Tawfik, Amany
AU - Al-Shabrawey, Mohamed
N1 - Funding Information:
The following grants support this study: AHA Grant-in-Aid grant ( AHASE00144 ) to M.-H Wang; (NIH R01EY023315) to M. Al-Shabrawey; AHA (18CDA34080403) to A. Ibrahim (ASI); and (NIH R01 EY029751-01 – NEI00072) to A. Tawfik.
Funding Information:
The following grants support this study: AHA Grant-in-Aid grant (AHASE00144) to M.-H Wang; (NIH R01EY023315) to M. Al-Shabrawey; AHA (18CDA34080403) to A. Ibrahim (ASI); and (NIH R01 EY029751-01 ? NEI00072) to A. Tawfik.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/6
Y1 - 2020/6
N2 - Clinical studies have suggested that the renin-angiotensin system (RAS) may be a promising therapeutic target in treating diabetic retinopathy (DR). While AT1 receptor blockade decreased the incidence of DR in the DIRECT trial, it did not reduce the DR progression. Lack of understanding of the molecular mechanism of retinal microvascular damage induced by RAS is a critical barrier to the use of RAS blockade in preventing or treating DR. The purpose of this study is to investigate the interaction between soluble epoxide hydrolase (sEH) and the AT1 receptor in Angiotensin II (Ang II)- and diabetes-induced retinal microvascular damage. We demonstrate that Ang II increases retinal sEH levels, which is blunted by an AT1 blocker; administration of 11,12-epoxyeicosatrienoic acid (EET) exacerbates intravitreal Ang II-induced retinal albumin leakage; while sEH knockout (KO) and blockade reduce Ang II-induced retinal vascular remodeling, sEH KO causes retinal vascular leakage in Ang II-sEH KO mice; and sEH KO potentiates diabetes-induced retinal damage via promoting retinal vascular endothelial growth factor (VEGF) but reducing expression of tight junction proteins (ZO-1 and occludin). Our studies hold the promise of providing a new strategy, the use of combined EETs blockade with AT1 blocker, to prevent or reduce DR.
AB - Clinical studies have suggested that the renin-angiotensin system (RAS) may be a promising therapeutic target in treating diabetic retinopathy (DR). While AT1 receptor blockade decreased the incidence of DR in the DIRECT trial, it did not reduce the DR progression. Lack of understanding of the molecular mechanism of retinal microvascular damage induced by RAS is a critical barrier to the use of RAS blockade in preventing or treating DR. The purpose of this study is to investigate the interaction between soluble epoxide hydrolase (sEH) and the AT1 receptor in Angiotensin II (Ang II)- and diabetes-induced retinal microvascular damage. We demonstrate that Ang II increases retinal sEH levels, which is blunted by an AT1 blocker; administration of 11,12-epoxyeicosatrienoic acid (EET) exacerbates intravitreal Ang II-induced retinal albumin leakage; while sEH knockout (KO) and blockade reduce Ang II-induced retinal vascular remodeling, sEH KO causes retinal vascular leakage in Ang II-sEH KO mice; and sEH KO potentiates diabetes-induced retinal damage via promoting retinal vascular endothelial growth factor (VEGF) but reducing expression of tight junction proteins (ZO-1 and occludin). Our studies hold the promise of providing a new strategy, the use of combined EETs blockade with AT1 blocker, to prevent or reduce DR.
KW - Angiotensin II
KW - Cytochrome P-450
KW - Diabetic retinopathy
KW - EETs
KW - RAS
UR - http://www.scopus.com/inward/record.url?scp=85084356563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084356563&partnerID=8YFLogxK
U2 - 10.1016/j.prostaglandins.2020.106449
DO - 10.1016/j.prostaglandins.2020.106449
M3 - Article
C2 - 32360774
AN - SCOPUS:85084356563
SN - 1098-8823
VL - 148
JO - Prostaglandins and Other Lipid Mediators
JF - Prostaglandins and Other Lipid Mediators
M1 - 106449
ER -
